SEARCH

SEARCH BY CITATION

References

  • Backlund M, Lindgren L, Kajimoto Y, Rosenberg PH (1997). Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anesth 9: 3035.
  • Beardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, Harris LS (2004). Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. Exp Clin Psychopharmacol 12: 163172.
  • Caraco Y, Sheller J, Wood AJ (1997). Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. J Pharmacol Exp Ther 281: 330336.
  • Chen ZR, Irvine RJ, Somogyi AA, Bochner F (1991). Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 48: 21652171.
  • Childers SR, Creese I, Snowman AM, Synder SH (1979). Opiate receptor binding affected differentially by opiates and opioid peptides. Eur J Pharmacol 55: 1118.
  • Cleary J, Mikus G, Somogyi A, Bochner F (1994). The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 271: 15281534.
  • Coluzzi F, Mattia C (2005). Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 71: 451460.
  • Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW (1983). Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 11: 446450.
  • Daali Y, Cherkaoui S, Doffey-Lazeyras F, Dayer P, Desmeules JA (2008). Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. J Chromatogr B Analyt Technol Biomed Life Sci 861: 5663.
  • Davis MP, Varga J, Dickerson D, Walsh D, Legrand SB, Lagman R (2003). Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11: 8492.
  • De Leon J, Dinsmore L, Wedlund P (2003). Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 23: 420421.
  • Desmeules J, Dayer P (1991). The role of debrisoquine oxidation polymorphism in the biotransformation of codeine into morphine and its analgesic effect. Douleur Analgesie 4: 7986.
  • Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G et al. (2004). Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60: 237246.
  • Falk E (1917). Eukodal ein neues Narkoticum. Munch Med Wochenschr 20: 381384.
  • Foster A, Mobley E, Wang Z (2007). Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract 7: 352356.
  • Fruhstorfer H, Lindblom U, Schmidt WC (1976). Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 39: 10711075.
  • Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P et al. (2004). Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351: 28272831.
  • Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K et al. (2009). Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65: 263271.
  • Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND (2007). Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 96: 24942506.
  • Heiskanen T, Olkkola KT, Kalso E (1998). Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64: 603611.
  • Hindmarch I (1980). Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 10: 189209.
  • Jones SF, Mcquay HJ, Moore RA, Hand CW (1988). Morphine and ibuprofen compared using the cold pressor test. Pain 34: 117122.
  • Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD (1996). Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59: 5261.
  • Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004). Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32: 447454.
  • Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79: 461479.
  • Lee HK, Lewis LD, Tsongalis GJ, Mcmullin M, Schur BC, Wong SH et al. (2006). Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 367: 196200.
  • Lemberg K, Kontinen VK, Viljakka K, Kylanlahti I, Yli-Kauhaluoma J, Kalso E (2006a). Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg 102: 17681774.
  • Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER et al. (2006b). Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105: 801812.
  • Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D (1996). Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 12: 182189.
  • Myers AB, Sullivan JE, Koller DM, Godambe SA, Kennedy MJ (2005). Correlation of CYP2D6 genotype with response to oxycodone in orthopedic injury related pain. Clin Pharmacol Ther 79: P18.
  • Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K et al. (2009). Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110: 13711378.
  • Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F et al. (2009). Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 65: 887894.
  • Nozaki C, Kamei J (2007). Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice. Eur J Pharmacol 560: 160162.
  • Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (1993). Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53: 401409.
  • Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C et al. (2009). The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 9: 3441.
  • Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL (2001). Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. J Clin Pharmacol 41: 224227.
  • Ross FB, Smith MT (1997). The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73: 151157.
  • Samer CF, Piguet V, Dayer P, Desmeules JA (2005). [Genetic polymorphism and drug interactions: their importance in the treatment of pain]. Can J Anaesth 52: 806821.
  • Samer CF, Desmeules JA, Dayer P (2006). Individualizing analgesic prescription part I: Pharmacogenetics of opioid analgesics. Personalized Med 3: 239269.
  • Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC et al. (2010). The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160: 907918.
  • Sandrini G, Serrao M, Rossi P, Romaniello A, Cruccu G, Willer JC (2005). The lower limb flexion reflex in humans. Prog Neurobiol 77: 353395.
  • Smith MT, Edwards SR, Nielsen CK (2007). Oxycodone's mechanism of action and potency differences after spinal and systemic routes of administration. Anesthesiology 106: 10631064. author reply 1064-5.
  • Susce MT, Murray-Carmichael E, De Leon J (2006). Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 30: 13561358.
  • Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K et al. (2006). Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34: 12771282.
  • Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE (2004). Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther 308: 547554.
  • Yarnitsky D, Ochoa JL (1990). Studies of heat pain sensation in man: perception thresholds, rate of stimulus rise and reaction time. Pain 40: 8591.
  • Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG (2002). Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303: 323332.
  • Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F et al. (2009). The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 104: 335344.